Search results for "Sars-Cov2"

showing 3 items of 23 documents

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficien…

2020

In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus statement on the tailoring of glucocorticoid replacement in adrenal insufciency [1]. A few months later, a novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has been recognized as responsible for COVID-19. The outbreak has now reached pandemic level, with a high global mortality rate [2]. From February on, Italy has experienced an exponential rise in the infected which is estimated to reach 200,000 people, with an overall lethality of approximately 10% [3]. A recent Chinese series of nearly 50,000 patients with confrmed COVID-19 infection found that approximately one-out-of-fve (19%) evolve …

medicine.medical_specialty2019-20 coronavirus outbreakConsensusCoronavirus disease 2019 (COVID-19)Hormone Replacement TherapyEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralConsensuEndocrinologyGlucocorticoidmedicineAdrenal insufficiencyHumansSteroids.Hormone replacement therapyViralIntensive care medicinePandemicsAdrenal insufficiency; COVID-19; Glucocorticoids; SARS-CoV2GlucocorticoidsPandemicbusiness.industryCoronavirus InfectionCOVID-19Pneumoniamedicine.diseaseCOVID-19 Drug TreatmentItalyExpert opinionSARS-CoV2SteroidsbusinessCoronavirus InfectionsCoronavirus InfectionsAdrenal insufficiencyHuman
researchProduct

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.

2022

Background and aims. Patients with Myasthenia gravis (MG) are considered vulnerable as they may present with respiratory muscle weakness and because they are on immunosuppressive treatment; thereby, COVID-19 may have a detrimental effect on these patients. Vaccines against COVID-19 are currently available and it has been shown as they can prevent severe COVID-19 in vulnerable patients. Notwithstanding their efficacy, vaccine hesitancy has not been completely dispelled in the general population. Unfortunately, there is limited data about the safety of these vaccines in MG patients. The aims of this study are to evaluate the impact of COVID-19 in a MG cohort, the adherence to COVID-19 vaccina…

myasthenic crisisvaccineCOVID-19; SARS-CoV2; vaccine; Myasthenia gravis; neuromuscular; myasthenic crisisSARS-CoV2COVID-19neuromuscularNeurology (clinical)Myasthenia gravisNeurology international
researchProduct

1,2,4-OSSADIAZOLI: UTILI SCAFFOLD NEL DESIGN DI NUOVI FARMACI

2021

quinazolinone(di)-acylguanidineneuroprotective agentreduction124-Oxadiazoleantidiabetic agentSARS-CoV2 proteaseSettore CHIM/06 - Chimica Organica
researchProduct